Target Price | $97.73 |
Price | $68.32 |
Potential |
43.05%
register free of charge
|
Number of Estimates | 26 |
26 Analysts have issued a price target Biomarin Pharmaceutical 2026 .
The average Biomarin Pharmaceutical target price is $97.73.
This is
43.05%
register free of charge
$126.00
84.43%
register free of charge
$65.00
4.86%
register free of charge
|
|
A rating was issued by 31 analysts: 25 Analysts recommend Biomarin Pharmaceutical to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2026 of
43.05%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.84 | 3.14 |
17.35% | 10.58% | |
EBITDA Margin | 22.06% | 27.94% |
78.58% | 26.67% | |
Net Margin | 14.85% | 19.26% |
114.00% | 29.71% |
26 Analysts have issued a sales forecast Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2025. The average Biomarin Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2025. The average Biomarin Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.21 | 3.17 |
151.14% | 43.44% | |
P/E | 21.55 | |
EV/Sales | 4.00 |
19 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Biomarin Pharmaceutical...
Analyst | Rating | Action | Date |
---|---|---|---|
Oppenheimer |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
Analyst Rating | Date |
---|---|
Locked
Oppenheimer:
Locked
➜
Locked
|
Feb 24 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 20 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 20 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.